US FDA approves Sanofi's genetic disorder drug
SNY•The FDA approved Sanofi's Infilbray for adults and children weighing at least 15 kilograms with type 3 Gaucher disease. In a 43-patient study, daily treatment for 52 weeks improved a combined measure of muscle control, coordination and cognitive function compared with enzyme replacement therapy.
1. FDA approval
The FDA approved Sanofi's oral drug venglustat, branded as Infilbray, as the first treatment for type 3 Gaucher disease, a rare inherited disorder that causes fatty substances to build up in the body and brain. The approval covers adults and children weighing at least 15 kilograms, or about 33 pounds.
2. Study results
The approval was based on a late-stage study of 43 patients aged 12 years and older whose symptoms outside the brain and nervous system had been stabilized with enzyme replacement therapy. Patients who took Infilbray once daily for 52 weeks improved on a combined measure of muscle control, coordination and cognitive function compared with those receiving enzyme replacement therapy every two weeks. Commonly reported side effects included gastrointestinal problems and effects on mood.




